Dear Colleague,
It is my pleasure to welcome you all in this conference entitled ‘’ Unanswered questions in clinical practice’’ organized in collaboration with the Saudi Society of Internal Medicine.
This conference will cover several important hot topics related to the management of breast and gastrointestinal cancers in addition to hematological malignancies with special focus on areas of debates with no conclusive scientific evidence.
We hope this meeting will bring us all up to date knowledge in the field of oncology and hematology with very interesting scientific program that focus on the debates in cancer management. Distinguished national speakers will join us on this conference and will share their experience with us. I hope this meeting will be an excellent educational experience and I wish you would enjoy the scientific sessions.
We are sure that your active participation will add to the value of this important oncology conference.
Finally, I would like to express my deep thanks to the organizing and scientific committee.
Thank You.
Dr. Khalofa Alghamdi
Director of Oncology Center
King Abdullah Medical City
Speakers
AGENDA AGENDA
Breast cancer
Dr. Hamdi Abdelazim
Dr. Ahmed Alfaraj
Dr. Ahmed Saadeldine
Advanced HER2-positive/HER2-low breast cancer
Patient with brain metastasis and stable extracranial disease: when to change antiHER2-based therapy
Patient with active brain metastasis: locoregional therapy vs systemic therapy
Patient with active brain metastasis: T-DXd vs.
tucatinib-based therapy
Can we use TDM1 after T-DXd
Role of repeated biopsies to guide ADCs in HER2-low BC
Moderator: 
Shereef Elsamany
Panel:
Dr. Ahmed Alfaraj
Dr. Om Alkhair Aboelkhair
Dr. Ahmed Alshehri
Role of anthracyclines in early breast cancer
- When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer
When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer
Moderator:
Dr. Meteeb Alfohaidi
Panel:
Satellite Symposium
Dr. Maha Alidrisi
Prof. Yasir Bahader
Dr. Mariam Alsulami
Can we de-escalate axillary surgery/omit adjuvant radiotherapy with excellent response after NAC?
Complete response to NAC
Residual ITCs after NAC
Controversies of targeted axillary dissection
SLNB: Negative LNs in frozen section/positive in final pathology
Negative SLNB after neoadjuvant hormonal therapy
Moderator:
Dr. Nasser Ali Al-Dhaibani 
Dr. Roaa Attieh
Panel:
Opening ceremony
Lunch & prayer
Satellite Symposium
Prof. Alaa Kandil
Dr. Meteb Alfoheidi
Dr. Fadi Farhat
Oncologists/pathologists dialogue TILS and descalation of systemic therapy in early breast cancer?
Moderator: 
Dr. Ahmed Alwbari 
Dr. Hatim Al Maghrabi
Dr. Hamdi Abdelazim
Dr. Adher Elsayed
Dr. Om Alkhair Aboelkhair
Genomic tools in breast cancer
- chemotherapy in high risk lobular/mucinous BC?
- Neoadjuvant therapy in premenopausal patients with lobular BC?
Adjuvant therapy with node negative and node positive lobular BC?
Adjuvant therapy in luminal BC with RS 16-25?
Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours?? - Oncotype DX and selection of neoadjuvant hormonal vs chemotherapy therapy
- Role of interval Ki67 assessment with neoadjuvant hormonal therapy
Moderator: 
Ahmed Alshehri
Panel:
Break
Dr. Nasr Al-lahloubi
Dr. Meteb Alfoheidi
Prof. Alaa Kandil
Transition from hormonal-based to chemotherapy in metastatic BC??
- Patients with early progression on CDK4-6 inhibitors: What is next??
- When to start ADCs/olaparib in patients who had visceral crisis?? Can be upfront??
- Any role of hormonal monotherapy after CDK4-6 inhibitors??
- Biomarkers to guide subsequent therapies
- Can we use one ADC after previous ADC??
Moderator: 
Dr. Ahmed Alfaraj
Panel:
Concluding remarks Day 1
Dr. Ali Aljubran
Dr. Mervat Mahrous
Dr. Marwan Alhejeeli
Setting-up clinical trials in Middle east: Challenges and opportunities
Moderators:
Dr. Emad Tashkandi 
Dr. Hosam Alghanmi
Panel:
Prof. Dirk Arnold
Dr. Ashwaq Alolayan
Dr. Samah Alraheli
Pancreatic cancer
- Neoadjuvant therapy in resectable/borderline resectable pancreatic cancer
- Best neoadjuvant strategy
- 1st line and subsequent therapies in pancreatic cancer: Doublet vs Triplets
- biomarkers for metastatic patients
Moderator: 
Dr. Abdullah Alsharm
Panel:
Dr. Ashwaq Alolayan
Dr. Fahed Ibn Shamsa
Dr. Kanan Alshammari
Biliary tract cancer
- Immunetherapy in advanced BTC: Yes/No
- Which agent?
- Patient selection/tumour location?
- Role of maintenance therapy?
- Role of liquid biopsy/biomarker assessment
Moderator: 
Dr. Mohammed Algarni
panel:
Break
Prof. Dirk Arnold
Dr. Nedal Bukhari
Dr. Samah Alraheli
Perioperative therapy in Gastric cancer
- Role of laparoscopy assessment before perioperative therapy?
- What to do in patients with poor response to neoadjuvant therapy?
- Role of biomarkers e.g MSI in decision-making before perioperative therapy?
- Patients with limited peritoneal metastasis: Role of HIPEC?
- Role of immunetherapy with perioperative therapy non-metastatic gastric cancer?
Moderator: 
Dr. Fahad Ibnshamsah
Dr. Abdullah Alsharm
Dr. Ahmed Alrefaei
Dr. Yousry Rostom
Challenges and dynamics of oncology health care
- Financial toxicities and economic burden
- Delayed access to oncology care
- Cancer survivors: challenges and special requirements
- Integration of service with primary health care for cancer survivors
Moderator: 
Dr. Esam Murshid
Panel:
Prof. Dirk Arnold
Immunetherapy in CRC: Transition from metastatic to early stage
Satellite Symposium
Closing remarks
Prayer &Lunch
Partners
Sponsors
InterContinental Jeddah Location
